Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738737 | 0.80 | LMNA (0.37) | CNR1CNR2LMNA | |
| SCHEMBL14738738 | 0.80 | LMNA (0.37) | CNR1CNR2LMNA | |
| SCHEMBL14738909 | 0.74 | PTGDR2 (0.39) | LMNA | |
| SCHEMBL7711534 | 0.74 | P2RX3 (0.38) | LMNA | |
| SCHEMBL14753488 | 0.73 | NPC1 (0.49) | NPC1RAB9ALMNA | |
| SCHEMBL7713726 | 0.72 | FAAH (0.47) | LMNA | |
| SCHEMBL7711943 | 0.71 | ROCK1 (0.53) | NPC1RAB9A | |
| SCHEMBL14739875 | 0.67 | NUDT1 (0.41) | NPC1RAB9APDE4BPDE4DBRD4 | |
| SCHEMBL14753478 | 0.67 | NUDT1 (0.41) | NPC1RAB9APDE4BPDE4DBRD4 | |
| SCHEMBL7716091 | 0.67 | FAAH (0.35) | CNR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102917707-A | Azaindole derivatives useful as modulators of FAAH | MERCK SHARP & DOHME | 2013-02-06 | — | — | CN | claimed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011140164-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | CNR1 17/4885CNR2 10/4885NPC1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.